Capricor Therapeutics (CAPR) vs MapLight Therapeutics (MPLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MapLight Therapeutics is the larger company by market cap ($490.7 million vs $455.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPR | MPLT |
|---|---|---|
| Share price | $7.83 | $8.83 |
| Market cap | $455.23M | $490.73M |
| 1-day change | -2.25% | -3.50% |
| YTD return | -72.25% | -47.91% |
| 1-year return | +7.09% | — |
| 5-year return | +102.27% | — |
| EPS (TTM) | $-2.45 | $-6.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.37 | $40.43 |
| 52-week low | $2.96 | $8.71 |
| Distance from 52-week high | -80.60% | -78.16% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +244.83% | +200.57% |
| Average volume | 6.87M | 851.70K |
| Shares outstanding | 58.14M | 52.85M |
| Employees | 231 | 133 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
About MapLight Therapeutics
MPLT stock →MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees
CAPR vs MPLT FAQ
Which is bigger, Capricor Therapeutics or MapLight Therapeutics?
MapLight Therapeutics (MPLT) is larger, with a market capitalization of $490.73M compared with $455.23M for Capricor Therapeutics (CAPR).
Are Capricor Therapeutics and MapLight Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.